Fig. 5From: The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDSCytokine analysis and comparison before and after treatment with EXO-CD24. Blood from all participating patients was collected at baseline and at Day 7 of the EXO-CD24 treatment. Cytokine and chemokine levels were analyzed using glass slide multiplex ELISA cytokine arrays according to the manufacturer instructions (Quantibody®, RayBiotech)Back to article page